from Atacand)Jump to: navigation, atacand weight gain (IUPAC) name3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-3H-benzo[d]imidazole-4-carboxylic acidIdentifiersCAS number 139481-59-7ATC code C09CA06PubChem 2541DrugBank APRD00420Chemical dataFormula C24H20N6O3Mol. mass.

(IUPAC) name3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-3H-benzo[d]imidazole-4-carboxylic acidIdentifiersCAS number 139481-59-7ATC code C09CA06PubChem 2541DrugBank APRD00420Chemical dataFormula C24H20N6O3Mol. mass 440.45Pharmacokinetic dataBioavailability 15% (candesartan cilexetil)Metabolism Candesartan cilexetil: intestinal wall; candesartan: hepatic (CYP2C9)Half life 5.1–10.5 hoursExcretion Renal atacand weight gain faecal 67%Therapeutic considerationsPregnancy cat. D (Au)Legal status atacand weight gain Prescription onlyRoutes oralCandesartan (rINN) (pronounced /?k?nd??s?rt?n/) is an angiotensin II atacand weight gain antagonist[edit] atacand weight gain with all angiotensin II receptor antagonists, candesartan is indicated for the treatment of atacand weight gain The prodrug candesartan cilexetil is marketed by AstraZeneca and Takeda Pharmaceuticals, commonly under the trade names Blopress, Atacand, Amias, and Ratacand.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diuretic2 Chemistry and pharmacokineticsCandesartan Chemistry.

developed in nearly two thirds of patients with chronic heart failure: the CHARM-Overall programme.". Lancet.